ASH 2019 – Orlando. The big “late-breaking” news at the American Society of Hematology Annual Meeting are the results of the phase III Candor trial. Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) in this video the main results of this clinical trial.
[embedyt] https://www.youtube.com/watch?v=gL03qX_sOm0&width=550&height=309&iv_load_policy=3¢ervid=1&rel=0&showinfo=0[/embedyt]
